About

Jonathan Chang, MD, is an Associate Professor in the Department of Ophthalmology and Visual Sciences at the University of Wisconsin–Madison. He serves as the Vitreoretinal Surgery Fellowship Co-Director, Associate Residency Program Director, and Associate Director for Subspecialty Retina, macula, and vitreous diseases. His medical and surgical interests include diabetic retinopathy, macular degeneration, myopia, ocular trauma, retinal detachment, retinal vascular disease, and vitreoretinal surgery. Dr. Chang's research focuses on the use of retrospective clinical data to review patient outcomes, the evaluation of physician and industry interactions through clinical databases and their impact on clinical care, the determination of cost-effectiveness and utility of clinical interventions, and the use of imaging to evaluate retinal diseases. His educational background includes a fellowship in Vitreoretinal Surgery at the Bascom Palmer Eye Institute in Miami, FL, a residency at the same institute, an internship at Mount Sinai Beth Israel in New York, NY, and medical school at Columbia University College of Physicians and Surgeons in New York, NY.

Research topics

• Medicine
• Internal medicine
• Oncology
• Immunology
• Gastroenterology
• Cancer research
• Family medicine
• Pathology

Selected publications

• The 2022 eruption of Mauna Loa, Hawaiʻi: a synoptic and retrospective overview of the eruption

  Bulletin of Volcanology · 2026-04-24 · 1 citations

  articleOpen access

  Abstract Mauna Loa volcano erupted on November 27, 2022, after 38 years of quiescence, marking the first eruption of the world’s largest active volcano since 1984. Precursory activity was characterized by escalating seismicity and ground deformation, with increased unrest beginning in mid-September 2022. At 22:24 HST, tilt and seismic alarms alerted Hawaiian Volcano Observatory staff to escalating activity, signaling an imminent eruption. The eruption began at 23:21 HST with lava fountains exceeding 120 m height in Mokuʻāweoweo caldera. En echelon fissures rapidly propagated northeastward across the caldera floor and southward into the upper Southwest Rift Zone. Summit activity peaked around 03:03 on November 28, 2022 and waned by 06:30. Fissure activity migrated into the Northeast Rift Zone with sequential opening of fissures (named NER_F1, NER_F2, NER_F3, and NER_F4). By December 1, fissure NER_F3A became the eruption’s dominant vent, characterized by sustained fountains of 25–40 m height and building a 30–48 m tall tephra cone. The eruption produced predominantly ʻaʻā lava flows extending 18 km long downslope, covering 36 km 2 with a total volume of 142 × 10 6 m 3 . Geochemical analyses revealed remarkably uniform bulk lava compositions across all eruptive locations. SO 2 emissions peaked at 363 kt/day on November 29, declining to undetectable levels by December 12. Activity declined markedly after December 7, with the eruption officially ending on December 12. The 2022 eruption characteristics—including duration (15 days), area coverage (36 km 2 ), volume, and flow length (18 km long)—closely matched the average parameters of historical Northeast Rift Zone eruptions over the past 200 years.

  PublisherOA PDFDOI

• NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025

  Journal of the National Comprehensive Cancer Network · 2025-10-01 · 9 citations

  article

  The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.

  PublisherDOI

• Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

  Blood · 2025-11-03

  articleOpen access

  Abstract Introduction Management of DLBCL in older adults (OA) is challenging, requiring a personalized approach that accounts for age-related comorbidities and frailty. Many OA receive non-anthracycline based treatment (tx), or attenuated regimens (i.e. R-miniCHOP) to avoid toxicity. However, DLBCL remains the leading cause of death for OA treated with these regimens. Torka et al (ASH 2024) defined a population with DLBCL at increased risk of developing severe toxicities (STox) from tx. Predictors of STox included age >75, ADL and IADL dependence, poor nutritional status, patient rated Karnofsky performance status (prKPS) ≤80 and timed up and go (TUG) time of ≥12 secs. SD R-CHOP is an alternative approach where pts receive CHOP at 50% dose reduction on days 1 and 15 of each 28-day cycle (C) with R on Day 1 for 6 cycles. The cumulative dose of one cycle of SD R-CHOP is equal to one cycle of R-CHOP-21. Interim data was previously presented at ASCO 2023. We present updated results including data from planned geriatric assessments (GA). Methods A Phase II, prospective, open label trial of SD-R-CHOP was conducted in frail OA through the WON. Eligible pts had untreated de-novo or transformed (t) DLBCL or high-grade B cell lymphoma NOS stage IIX-IV with KPS ≥ 50 and were either age ≥ 75 years old or 70-74 years with a Cumulative Illness Rating scale for Geriatrics (CIRS-G) of at least 10 or ≥1 comorbidity scored 3-4. Pts with CNS involvement were excluded. Impaired organ function was permitted as long as R-CHOP agents were not contraindicated. Pre-phase steroids and intrathecal CNS prophylaxis were allowed but not required. G-CSF support was mandatory. Tx consisted of two cycles of SD R-CHOP followed by interim response assessment with PET/CT and peripheral blood clonoSEQ MRD testing. Pts with interim PET/CT score of Deauville 1-3 and undetectable (u) MRD were offered abbreviated therapy with two additional cycles of SD-R-CHOP. All others completed 6 cycles of tx. Dose reductions for cytopenias were not permitted. Subsequent dose was delayed until tx parameters were met, up to 28 days. Pts were evaluated prospectively using the Cancer and Aging Research Group (CARG) GA at baseline, interim disease assessment, and end of tx (EOT). The primary endpoint was EOT complete response (CR) rate. A Simon 2-stage design was used with a target of 16 of 26 pts (>60%) achieving an EOT CR to consider this regimen successful. Results 26 pts received at least one dose of SD-R-CHOP. The median age was 80 years (71-88) and most had stage III/IV disease (85%). IPI was ≥ 3 for all, and 6 pts (23%) had tDLBCL. 20 pts (77%) had KPS ≤80, and 14 (56%) had prKPS ≤80. At baseline 12 of 26 (48%) had impaired IADLs, 5/25 (20%) had impaired ADL and TUG was ≥12 secs for 20 (77%) pts, with a median TUG of 20 secs (IQR 12-75). 7 pts were unable to perform baseline TUG. The EOT CR rate for all pts was 65% (n=17) exceeding target threshold. Nine pts (35%) were both uMRD/PET- at interim assessment after C2; of these, 8 completed abbreviated tx, while one opted for a full 6 cycles. Eight of these 9 pts (89%) achieved an EOT CR. 17 pts were assigned to the full tx arm (6 cycles) due to interim MRD+ or PET+ and in this group, the EOT CR rate was 53%. At 18-months, overall survival (OS) was 67% and progression free survival (PFS) was 58%. Neither median OS nor PFS were reached to date. Only one pt with interim uMRD/PET- has relapsed to date despite 8 of 9 receiving abbreviated therapy. Grade 4+ toxicity occurred in 13 pts (50%) and SAE in 9 (35%). 15 pts (58%) had a dose modification/delay. 3 pts (12%) had >1 dose delay, 4 (15%) had >1 cycle at reduced dosing. Two pts (7.6%) experienced non-relapse mortality: 1 infection, 1 cardiac event possibly related to tx. No component of the CARG GA predicted STox in this cohort. Conclusions SD-R-CHOP offers frail OA with DLBCL equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule. The EOT CR rate for all pts was 65% exceeding the Phase II threshold set for this trial, demonstrating the value of maintaining dose intensity for older pts. Despite significant comorbidity and a high prevalence of factors associated with STox, events were less common than expected in this group. De-escalation of therapy appears feasible for pts with interim uMRD/PET- response, limiting toxicity without impacting long-term outcomes. These findings suggest that SD R-CHOP warrants further study in frail OA with DLBCL at high risk for STox.

  PublisherOA PDFDOI

• Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with <i>KRAS G12C</i>-positive non-small cell lung cancer (NSCLC)

  Cancer Research · 2025-04-25

  article

  Abstract Introduction: Divarasib (GDC-6036), an oral, highly potent, and selective next-generation KRAS G12C inhibitor (KRAS G12Ci), has shown encouraging clinical activity and tolerability as a single agent in patients with KRAS G12C-positive NSCLC. In pre-clinical models, SHP2 inhibition increases KRAS-GDP occupancy and enhances the antitumor activity of KRAS G12C inhibitors. Here, we report clinical safety and activity of combination divarasib and migoprotafib (GDC-1971; SHP2 inhibitor) in patients with NSCLC. Methods: As part of an ongoing phase I study (NCT04449874), patients received divarasib 200 mg or 400 mg daily in combination with oral migoprotafib 20, 40, or 60 mg daily, until intolerable toxicity or disease progression. Safety (NCI-CTCAE v5), pharmacokinetics, and preliminary antitumor activity (RECIST v1.1) were assessed. Circulating tumor DNA (ctDNA) analyses were performed at Cycle 1 Day 1 and Cycle 3 Day 1. Results: As of April 1, 2024, a total of 74 patients with NSCLC received combination divarasib and migoprotafib; 48 patients had no prior KRAS G12Ci exposure. Median lines of prior systemic therapy was 2 (range 0-7) and median time on study treatment was 7.2 months (range 0.3-26.0). Overall, 70 (94.6%) patients experienced at least one treatment-related adverse event (TRAE); the most common TRAEs (≥15%) were diarrhea, nausea, vomiting, peripheral edema, increased blood creatine phosphokinase, fatigue, increased amylase, increased aspartate aminotransferase and increased alanine aminotransferase. Grade 3-4 TRAEs occurred in 32 (43.2%) patients, including diarrhea in 11 (14.9%) patients, increased ALT in 4 (5.4%) patients, and pneumonitis, thrombocytopenia, and neutropenia in 3 (4.1%) patients each. There were no Grade 5 TRAEs. TRAEs led to divarasib dose reduction in 23 (31.1%) patients and migoprotafib dose reduction in 32 (43.2%) patients. Divarasib discontinuation due to TRAEs occurred in 2 (2.7%) patients; migoprotafib discontinuations due to TRAEs occurred in 5 (6.8%) patients. The pharmacokinetic profiles of both divarasib and migoprotafib in combination were similar to their respective single-agent profiles. Among the 48 patients who had no prior KRAS G12Ci exposure (all of whom had measurable disease at baseline), the confirmed ORR was 43.8% and the median PFS was 15.2 months (CI 95% 8.4-not estimated). A decline in ctDNA level was observed at Cycle 3 Day 1 upon divarasib plus migoprotafib treatment, similar to single-agent divarasib treatment. Updated data will be presented for patients both with and without prior KRAS G12Ci exposure. Conclusion: Divarasib in combination with migoprotafib demonstrated an acceptable safety profile and preliminary clinical activity in patients with KRAS G12C-positive NSCLC. Citation Format: Jia Luo, Adrian Sacher, Armando Santoro, Luis Paz-Ares, Sanjeev Deva, Hans Prennen, Maria de Miguel, Rafal Dziadziuszko, Scott A. Laurie, Manish R. Patel, Elena Garralda, Gianluca Del Conte, Loes Latten Jansen, Jayesh Desai, Rita De Cassia Costamilan, Patricia LoRusso, Ben Markman, Salvatore Siena, Pierre Freres, Marloes Van Dongen, Eugenio Fernandez, Andres Cervantes, Josiane Mourão Dias, Sergio Azevedo, Kathryn Arbour, Ruth Perets, Se Hyun Kim, Rasha Cosman, Victor Moreno, Matthew G. Krebs, Yoonha Choi, Sandhya Mandlekar, Mark T. Lin, Zhen Shi, Kenneth K. Yau, Julie Chang, Stephanie Royer-Joo, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, Myung-Ju Ahn. Divarasib plus migoprotafib combination treatment in patients with KRAS G12C-positive non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT022.

  PublisherDOI

• ABCL-1407: Split-Dose R-CHOP With Interim De-Escalation of Therapy in Elderly Patients With Diffuse Large B-cell Lymphoma

  Clinical Lymphoma Myeloma & Leukemia · 2025-08-28

  article
  PublisherDOI

• POSTER: ABCL-1407 Split-Dose R-CHOP With Interim De-Escalation of Therapy in Elderly Patients With Diffuse Large B-cell Lymphoma

  Clinical Lymphoma Myeloma & Leukemia · 2025-08-28

  article
  PublisherDOI

• EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

  Leukemia & lymphoma/Leukemia and lymphoma · 2023-03-24 · 8 citations

  article

  The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity. EBV + tumors were associated with absent C-MYC and BCL6 expression. EBV + PTLD was more likely to be associated with the absence of CD5 expression. EBV + non-PTLD had better median OS (not reached) compared to EBV + PTLD (10.8 months) and EBV-negative patients (43 months). Multivariable Cox regression analysis showed that age, performance status, and PTLD were negative predictors of OS. EBV status and immunosuppressive treatment were not correlated with OS. Our findings merit further investigation of EBV + PCNSL tumors and EBV-directed therapies.

  PublisherDOI

• Time-series petrologic and geochemical monitoring of the 2022 eruption of Mauna Loa, Hawai‘i

  2023-01-01 · 1 citations

  articleOpen access
  PublisherOA PDFDOI

• Data from Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

  2023-03-31

  preprintOpen access

  &lt;div&gt;Abstract&lt;p&gt;&lt;b&gt;Purpose:&lt;/b&gt; Signaling through the fibroblast growth factor (FGF) pathway may account for tumor resistance to antiangiogenic therapies targeting the VEGF pathway. Here, dovitinib (TKI258), a potent oral inhibitor of FGF receptor, VEGF receptor (VEGFR), and platelet-derived growth factor receptor tyrosine kinases, is studied in a dose escalation trial.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Experimental Design:&lt;/b&gt; Patients with advanced or metastatic renal cell carcinoma (RCC) with predominant clear cell histology were treated with oral dovitinib 500 or 600 mg/day (5-days-on/2-days-off schedule).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; Twenty heavily pretreated patients (median 3 prior regimens) were enrolled, with 16, 11, and 12 patients having previously received at least 1: VEGFR inhibitor, mTOR inhibitor, and immunotherapy, respectively. Fifteen and 5 patients were treated in 500- and 600-mg cohorts, respectively. Three patients experienced dose-limiting toxicities: grade 2 bradycardia (500 mg), grade 4 hypertensive crisis (600 mg), and grade 3 asthenia with grade 2 nausea and vomiting (600 mg). The most common adverse events related to dovitinib were nausea (75%), diarrhea (70%), vomiting (70%), and asthenia (50%), the majority of which were mild (grade 1 or 2), with grade 3 events 5% or less (except asthenia, 15%) and only one grade 4 event (hypertensive crisis). Two patients achieved a partial response (500 mg), and 12 patients had stable disease, including 2 patients with long lasting disease stabilizations (&gt;1 year) in the 500-mg cohort.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Dovitinib was tolerable and showed antitumor activity at a maximum tolerated dose of 500 mg on a 5-days-on/2-days-off schedule in heavily pretreated RCC patients. &lt;i&gt;Clin Cancer Res; 19(5); 1257–68. ©2012 AACR&lt;/i&gt;.&lt;/p&gt;&lt;/div&gt;

  PublisherDOI

• Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 <scp>U.S.</scp> cancer centers

  American Journal of Hematology · 2023-03-25 · 25 citations

  articleOpen access

  There is a paucity of large-scale data delineating outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL patients ages ≥60 years across 20 U.S. academic centers. The median age was 70 years (range 60-88); at least one geriatric syndrome was present in 46%; the median Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score was 6 (range, 0-27); and 36% had impairment in activities of daily living (ADL). The most common induction regimens were high-dose methotrexate (HD-MTX) ± rituximab; methotrexate, temozolomide, rituximab (MTR); and rituximab, methotrexate, procarbazine, vincristine (R-MPV). Overall, 70% of patients achieved remission, with 14% undergoing consolidative autologous stem cell transplant (ASCT) and 24% receiving maintenance. With 58-month median follow-up, median progression-free survival (PFS) and overall survival (OS) were 17 months (95% CI 13-22 months) and 43 months (95% CI 31-56 months), respectively. Three-year PFS and OS were highest with MTR (55% and 74%, respectively). With single-agent methotrexate ± rituximab, 3-year PFS and OS were 30% (p = .0002) and 47% (p = .0072). On multivariate analysis, increasing age at diagnosis and Cooperative Oncology Group (ECOG) performance status (PS) was associated with inferior PFS; age, hypoalbuminemia, higher CIRS-G score, and ECOG PS adversely affected OS. Among patients receiving maintenance, 3-year PFS was 65% versus 45% without maintenance (p = 0.02), with 3-year OS of 84% versus 61%, respectively (p = .0003). Altogether, outcomes in older PCNSL patients appeared optimized with HD-MTX combination induction regimens and maintenance therapy. Furthermore, several prognostic factors, including geriatric measures, were associated with inferior outcomes.

  PublisherOA PDFDOI

Frequent coauthors

• Brad S. Kahl

  22 shared

• Daniel Castellano

  Hospital Universitario 12 De Octubre

  19 shared

• Julie M. Vose

  19 shared

• Eric Angevin

  19 shared

• Jürgen E. Gschwend

  Technical University of Munich

  19 shared

• Andrea L. Harzstark

  Kaiser Permanente San Francisco Medical Center

  19 shared

• Michael Shi

  18 shared

• José A. López-Martín

  18 shared

Labs

• A-EYE Research UnitPI

Education

• M.D., Ophthalmology

  University of Wisconsin–Madison

  2006

• B.S., Biology

  University of California, San Diego

  2002